Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | glycogen synthase kinase 3, putative | 0.0059 | 0 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.0059 | 0 | 0.5 |
Giardia lamblia | Kinase, CDC7 | 0.0981 | 1 | 1 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0059 | 0 | 0.5 |
Onchocerca volvulus | 0.0981 | 1 | 1 | |
Toxoplasma gondii | cell-cycle-associated protein kinase GSK, putative | 0.0059 | 0 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0981 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0981 | 1 | 1 |
Echinococcus multilocularis | CDC7 cell division cycle 7 | 0.0981 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0981 | 1 | 1 |
Echinococcus granulosus | CDC7 cell division cycle 7 | 0.0981 | 1 | 1 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0059 | 0 | 0.5 |
Onchocerca volvulus | 0.0981 | 1 | 1 | |
Plasmodium falciparum | glycogen synthase kinase 3 | 0.0059 | 0 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0059 | 0 | 0.5 |
Plasmodium vivax | glycogen synthase kinase 3, putative | 0.0059 | 0 | 0.5 |
Loa Loa (eye worm) | CDC7 protein kinase | 0.0981 | 1 | 1 |
Leishmania major | glycogen synthase kinase, putative;with=GeneDB:LinJ18_V3.0270 | 0.0059 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0981 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = -5 % | DNDI: Inhibition of Human African Trypanosomiasis, SBRI 427, in vitro at 2 ug.mL-1 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.